Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

Key Inclusion Criteria: For All Cohorts: * Adult ≥ 18 years old. * Metastatic disease not amenable to potentially curative surgery and with available archival tumor tissue or fresh tumor tissue biopsy. * Presence of at least 1 measurable lesion assessed by CT and/or MRI according to RECIST 1.1. * Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1. * Adequate bone marrow and organ function per defined criteria in the protocol. * Recovered from acute laboratory and clinical toxicities of prior anti cancer treatment to NCI CTCAE v5.0 grade ≤1 at time of screening, except alopecia and amenorrhea. For Cohort A: • First line metastatic colorectal adenocarcinoma. For Cohort B: • Second line metastatic colorectal adenocarcinoma that has progressed on prior line of chemotherapy administered for metastatic disease and which must include a fluoropyrimidine and oxaliplatin. For Cohort C: • Second line metastatic gastroesophageal adenocarcinoma that has progressed on prior line of chemotherapy administered for metastatic disease, and which must include a platinum agent and fluoropyrimidine doublet. For Cohort D: • Second or third line metastatic renal cell carcinoma with a clear cell component and has received one or two lines of treatment for metastatic disease that included an anti angiogenic agent for at least 4 weeks with radiologic progression on that treatment. For subjects starting from Part 1a in Cohorts A and B: * Serum hs CRP at screening ≥ 10 mg/L (per central laboratory assessment). * Not requiring immediate initiation of anti cancer therapy per investigator's best judgement. For subjects starting from Part 2 in Cohort C: • Serum hs CRP at screening ≥ 10 mg/L (per central laboratory assessment). Key Exclusion Criteria: For All Cohorts: * Currently receiving any of the prohibited medications or has contraindications as outlined in the 'Contraindications' to SOC regimen components. * Symptomatic brain metastases or brain metastases that require directed therapy (such as focal radiotherapy or surgery). * Suspected or proven immunocompromised state, or infections (as defined in the protocol). * Conditions that have a high risk of clinically significant bleeding after administration of anti VEGF agents. * Clinically significant, uncontrolled or recent (within last 6 months) cardiovascular disease. For Cohort D: * Concomitant medications, herbal supplements, and/or fruits and their juices that are known as strong inhibitors or inducers of CYP3A4/5, and medications that have a narrow therapeutic window and are predominantly metabolized through CYP3A4/5. * Impairment of GI function or GI disease that may significantly alter the absorption of cabozantinib. Other protocol-defined inclusion/exclusion criteria may apply